Eloxx Pharmaceuticals (ELOX) Reports Q2 Loss of $0.42/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. TMUS
7. SPY
8. CVS
9. UNH
10. AXP

Go back to Eloxx Pharmaceuticals (ELOX) Reports Q2 Loss of $0.42/Share

Eloxx Pharmaceuticals Reports Second Quarter 2018 Financial and Operating Results and Provides Business Update

August 7, 2018 4:01 PM EDT

CTA approved in Belgium and IND open in the U.S. for investigational drug candidate, ELX-02

On track to initiate Phase 2 clinical trials in cystic fibrosis and cystinosis in 2018

Expanded Leadership Team with Global Pharmaceutical Executives to Accelerate Growth

Company to host webcast and conference call on Tuesday, August 7, 2018 at 4:30 pm ET

WALTHAM, Mass., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel... More